The proliferating cell nuclear antigen (PCNA) is required for DNA replication and DNA nucleotide excision repair. Considerable evidence points to PCNA expression being a marker of proliferation in many situations. However, while levels of PCNA are normally very low in non-cycling tissues, high levels of the protein have been observed in the normal tissues surrounding human breast and pancreatic tumours. Using two model systems we have shown that PCNA is induced in non-cycling cells by adjacent transplanted tumour cells and that this phenomenon may be mimicked by the in vivo administration of growth factors (transforming growth factor alpha and epidermal growth factor). These data suggest that tumours may elaborate factors that induce PCNA e...
^To whom correspondeDce should be addressed The association of the proliferating cell nuclear antige...
Cell proliferation of 40 peripheral, node-negative non-small cell lung cancers (NSCLC) treated with ...
Cell proliferation of 40 peripheral, node-negative non-small cell lung cancers (NSCLC) treated with ...
The proliferating cell nuclear antigen (PCNA) is required for DNA replication and DNA nucleotide exc...
A major stimulus to study cell proliferation, particularly in rodent carcinogenicity assays and huma...
Proliferating cell nuclear antigen (PCNA) appears in the cell nuclei during the late G1 to S phases ...
<div><p>Cell proliferation in primary and metastatic tumors is a fundamental characteristic of advan...
Cell proliferation in primary and metastatic tumors is a fundamental characteristic of advanced brea...
Evidence is presented that association of proliferating cell nuclear antigen (PCNA) with nuclear chr...
The proliferating cell nuclear antigen (PCNA), also known as cyclin and DNA polymerase delta auxilia...
To investigate the expression of a marker of cell proliferation (PCNA/Cyclin) and its putative relat...
Thirty-five endocrine tumors of the pancreas, 17 functioning and 18 nonfunctioning, were immunohisto...
Results generated by the immunohistochemical staining with PC10, a new monoclonal antibody recognizi...
AbstractIn order to clarify the status of PCNA in normal and transformed cells, we performed analysi...
<p>(A) Immunohistochemical staining analysis. PCNA-positive cells in the sections are stained brown....
^To whom correspondeDce should be addressed The association of the proliferating cell nuclear antige...
Cell proliferation of 40 peripheral, node-negative non-small cell lung cancers (NSCLC) treated with ...
Cell proliferation of 40 peripheral, node-negative non-small cell lung cancers (NSCLC) treated with ...
The proliferating cell nuclear antigen (PCNA) is required for DNA replication and DNA nucleotide exc...
A major stimulus to study cell proliferation, particularly in rodent carcinogenicity assays and huma...
Proliferating cell nuclear antigen (PCNA) appears in the cell nuclei during the late G1 to S phases ...
<div><p>Cell proliferation in primary and metastatic tumors is a fundamental characteristic of advan...
Cell proliferation in primary and metastatic tumors is a fundamental characteristic of advanced brea...
Evidence is presented that association of proliferating cell nuclear antigen (PCNA) with nuclear chr...
The proliferating cell nuclear antigen (PCNA), also known as cyclin and DNA polymerase delta auxilia...
To investigate the expression of a marker of cell proliferation (PCNA/Cyclin) and its putative relat...
Thirty-five endocrine tumors of the pancreas, 17 functioning and 18 nonfunctioning, were immunohisto...
Results generated by the immunohistochemical staining with PC10, a new monoclonal antibody recognizi...
AbstractIn order to clarify the status of PCNA in normal and transformed cells, we performed analysi...
<p>(A) Immunohistochemical staining analysis. PCNA-positive cells in the sections are stained brown....
^To whom correspondeDce should be addressed The association of the proliferating cell nuclear antige...
Cell proliferation of 40 peripheral, node-negative non-small cell lung cancers (NSCLC) treated with ...
Cell proliferation of 40 peripheral, node-negative non-small cell lung cancers (NSCLC) treated with ...